# Nano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery.

> **NCT06772428** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 96 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors

## Interventions

- **DRUG:** Nano-crystalline Megestrol Acetate Oral Suspension
- **RADIATION:** standard treatment

## Key facts

- **NCT ID:** NCT06772428
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06772428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06772428, "Nano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery.". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06772428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*